Developing targeted therapies for neuroinflammatory diseases caused by autoantibodies.
Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
This study is looking for specific antibodies that might be causing neuroinflammatory diseases, and it aims to develop new treatments that can directly target the harmful cells involved, helping people who are affected by these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10973347 on NIH RePORTER |
What this research studies
This research focuses on identifying autoantibodies that attack cell surface antigens and may cause neuroinflammatory diseases. By using advanced techniques like single-cell sequencing, the team will create human monoclonal antibodies that can be tested in animal models. These models will help in understanding the disease mechanisms and developing targeted treatments, including engineered T cells and antibodies that specifically target the harmful B cells producing these autoantibodies. The goal is to create effective therapies that can directly address the underlying causes of these diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neuroinflammatory diseases associated with autoantibodies.
Not a fit: Patients with neuroinflammatory diseases not linked to autoantibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatments for patients suffering from neuroinflammatory diseases linked to autoantibodies.
How similar studies have performed: Other research has shown promise in using targeted therapies for autoimmune conditions, suggesting potential success for this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Pleasure, Samuel Jeremy — University of California, San Francisco
- Study coordinator: Pleasure, Samuel Jeremy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.